The study was limited to sequencing of CD19-enriched material and therefore focussed on the CLL fraction, but future endeavours will also allow for exploration of the myeloid and T-cell compartments before and after treatment, which was beyond the scope of this report. The gene discussed is CD19; the disease is B-cell chronic lymphocytic leukemia.